相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Sequence analysis of mutations and translocations across breast cancer subtypes
Shantanu Banerji et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Magdalena Cizkova et al.
BREAST CANCER RESEARCH (2012)
PTEN Level in Tumor Suppression: How Much Is Too Little?
Arkaitz Carracedo et al.
CANCER RESEARCH (2011)
PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors
Francesco Dituri et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
B. Weigelt et al.
ONCOGENE (2011)
Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
Rama Krishna Kancha et al.
PLOS ONE (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Carol O'Brien et al.
CLINICAL CANCER RESEARCH (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Krishna M. Vasudevan et al.
CANCER CELL (2009)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
Heikki Joensuu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
Laura E. MacConaill et al.
PLOS ONE (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation
Katsutoshi Oda et al.
CANCER RESEARCH (2008)
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation
Torsten Trowe et al.
CLINICAL CANCER RESEARCH (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
Gizeh Perez-Tenorio et al.
CLINICAL CANCER RESEARCH (2007)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas
JW Lee et al.
CLINICAL CANCER RESEARCH (2006)
The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells
JJ Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells
SJ Isakoff et al.
CANCER RESEARCH (2005)
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype
J Frasor et al.
ENDOCRINOLOGY (2003)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
